Cargando…
Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
INTRODUCTION: Multiple Sclerosis (MS) has a complex pathophysiology that involves genetic and environmental factors. DNA methylation (DNAm) is one epigenetic mechanism that can reversibly modulate gene expression. Cell specific DNAm changes have been associated with MS, and some MS therapies such as...
Autores principales: | Xavier, Alexandre, Campagna, Maria Pia, Maltby, Vicki E., Kilpatrick, Trevor, Taylor, Bruce V., Butzkueven, Helmut, Ponsonby, Anne-Louise, Scott, Rodney J., Jokubaitis, Vilija G., Lea, Rodney A., Lechner-Scott, Jeannette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266220/ https://www.ncbi.nlm.nih.gov/pubmed/37325639 http://dx.doi.org/10.3389/fimmu.2023.1162796 |
Ejemplares similares
-
Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity
por: Campagna, Maria Pia, et al.
Publicado: (2022) -
Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis
por: Campagna, Maria Pia, et al.
Publicado: (2023) -
Epigenome-wide association studies: current knowledge, strategies and recommendations
por: Campagna, Maria Pia, et al.
Publicado: (2021) -
Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis
por: Maltby, Vicki, et al.
Publicado: (2023) -
DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes
por: Xavier, Alexandre, et al.
Publicado: (2023)